Who is sponsoring NCT04608123?

NCT04608123 is sponsored by University Hospital, Grenoble.

What drugs are being tested in NCT04608123?

Interventions in NCT04608123: none (observational study).

What condition does NCT04608123 study?

NCT04608123 studies Parkinson's Disease (Disorder).

Is NCT04608123 still recruiting?

NCT04608123 is currently completed. Last updated 2 November 2020.

Last reviewed 2020-11-02 · How we verify

NCT04608123: PSYCHOSTIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Deep Brain Stimulation on Neuropsychiatric Fluctuations in Patients With Parkinson's Disease

Completed Last updated 2 November 2020

What this trial tests

trial testing none (observational study) in Parkinson's Disease (Disorder) in 31 participants. Completed in 21 July 2020.

Timeline

1 May 2020

Primary endpoint
21 July 2020

21 July 2020

Quick facts

Lead sponsor	University Hospital, Grenoble
Status	Completed
Study type	OBSERVATIONAL
Enrollment	31
Start date	1 May 2020
Primary completion	21 July 2020
Estimated completion	21 July 2020
Sites	1 location across France

Drugs / interventions tested

none (observational study)

Conditions studied

Parkinson's Disease (Disorder) — all drugs for Parkinson's Disease (Disorder) →

Sponsor

University Hospital, Grenoble

Who can join

Eligibility, any sex, with Parkinson's Disease (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Retrospective, monocentric, observational study designed to evaluate the effects of Bilateral Subthalamic Nucleus Deep Brain Stimulation (DBS STN) on Neuropsychiatric fluctuations in Patients with Parkinson's Disease (PD)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Deciphering the effects of STN DBS on neuropsychiatric fluctuations in Parkinson's disease.
Muldmaa M, Schmitt E, Infante R, Kistner A, et al · · 2024 · cited 1× · PMID 39461967 · DOI 10.1038/s41531-024-00811-1

Verify or expand the search:

Other trials of none (observational study)

Trials testing the same drug.

NCT04644419 — Chemotherapy-related Cognitive Impairment and Acute Leukemia · completed
NCT03318224 — Fatigue Prevalence, Severity, and State of Treatment in Germany · completed

Other University Hospital, Grenoble trials

Trials by the same sponsor.

NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04608123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
Last refreshed: 2 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04608123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing